PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

Summary

The primary objective of the study is to determine the pharmacokinetic (PK) profile of multiple doses of natalizumab in pediatric subjects with relapsing-remitting multiple sclerosis (RRMS). The secondary objectives are as follows: to characterize the pharmacodynamic (PD) profile of natalizumab (as defined by α4 integrin binding) and to explore the safety and tolerability of multiple doses of natalizumab in the pediatric population.

Timeline

Start

2013-07

Primary completion

2014-09

Completion

2014-09

Drugs

Indications